Purple Biotech (PPBT) AI Stock Analysis

• Market Cap: 24.99M
• Dividend Yield: N/A
• Average Volume (3M): 1.15M
• Price to Earnings (P/E): ―
• Beta (1Y): -0.54
• Revenue Growth: N/A
• EPS Growth: 71.51%
• Country: IL
• Employees: 9
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -0.30
• Shares Outstanding: 567,961,800
• 10 Day Avg. Volume: 2,213,406
• 30 Day Avg. Volume: 1,145,530
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.49
• Enterprise Value/Market Cap: >-0.01
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: <0.01
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 32 Underperform
• Price Target: ―

Purple Biotech struggles with significant financial challenges, including negative profitability and cash flow issues, heavily impacting its stock score. The technical analysis indicates a bearish trend, with some potential for a rebound given oversold conditions. Valuation remains unattractive due to negative earnings, further contributing to a low overall score.

Purple Biotech Business Overview & Revenue Model

Company Description

Purple Biotech Ltd. (NASDAQ: PPBT) is a clinical-stage pharmaceutical company focused on developing innovative therapies that target cancer and other chronic diseases. The company specializes in oncology and immunology, leveraging its proprietary drug discovery platforms to advance a pipeline of novel drug candidates. Purple Biotech aims to address unmet medical needs through its research and development efforts, with a commitment to improving patient outcomes and enhancing the quality of life for individuals battling severe illnesses.

How the Company Makes Money

Purple Biotech generates revenue primarily through partnerships, licensing agreements, and collaborations with other pharmaceutical companies. These agreements often involve upfront payments, milestone payments based on the achievement of specific development or regulatory milestones, and royalties on sales if the partnered products reach the market. Additionally, the company may receive research grants and funding from governmental and non-governmental organizations to support its R&D activities. Revenue streams are also bolstered by strategic alliances that facilitate the advancement and commercialization of its drug candidates, thereby expanding its market reach and enhancing potential returns on investment.

Purple Biotech Financial Statement Overview

Summary

Purple Biotech faces significant challenges with revenue generation and profitability, as seen in its income statement. The balance sheet reflects a strong equity position but lacks leverage, potentially limiting growth opportunities. Cash flow issues persist, with negative operating and free cash flow impacting financial flexibility. Overall, the company needs to address its revenue generation and operational efficiency to improve its financial health.

Income Statement

Purple Biotech has consistently struggled with generating revenue, with total revenues dropping to zero in most recent years. The company experiences significant net losses, and profit margins are negative, indicating poor profitability. EBIT and EBITDA margins are also negative, showing operational challenges. Historical revenue growth is nonexistent, and the company has not demonstrated an ability to turn around its revenue trajectory.

Balance Sheet

Despite negative net income, Purple Biotech maintains a relatively strong stockholders' equity position due to low total liabilities. The equity ratio remains high, reflecting a strong equity base. However, the debt-to-equity ratio is low, signifying limited leverage, which may constrain growth. The return on equity is negative, indicating inefficiency in generating returns from the equity base.

Cash Flow

The company reports persistent negative operating and free cash flow, indicating poor cash generation from operations. Despite this, Purple Biotech has managed its cash reserves reasonably well, maintaining positive cash balances. The free cash flow to net income ratio is negative, indicating that operations are not supporting profitability.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	195.80K	0.00	0.00	1.00M
Gross Profit	0.00	-196.00	-120.00	-55.00	999.94K
EBITDA	-7.05M	-22.23M	-21.49M	-17.52M	-28.41M
Net Income	-7.24M	-19.88K	-21.67M	-18.38M	-28.00M
Balance Sheet
Total Assets	37.04M	44.30M	54.62M	70.20M	83.80M
Cash, Cash Equivalents and Short-Term Investments	8.52M	15.41M	32.11M	47.20M	57.80M
Total Debt	183.00K	351.00K	515.00K	749.00K	895.00K
Total Liabilities	4.13M	10.01M	7.52M	5.09M	4.05M
Stockholders Equity	32.86M	34.21M	46.91M	64.83M	79.39M
Cash Flow
Free Cash Flow	-14.37M	-19.93M	-16.96M	-15.19M	-12.25M
Operating Cash Flow	-14.37M	-19.93M	-16.73M	-15.07M	-12.09M
Investing Cash Flow	509.00K	13.88M	19.91M	13.41M	-49.59M
Financing Cash Flow	6.77M	5.45M	1.11M	1.51M	68.49M

Purple Biotech Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 4.70
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:PPBT, the sentiment is Neutral. The current price of 4.7 is above the 20-day moving average (MA) of 4.19, above the 50-day MA of 4.24, and below the 200-day MA of 5.65, indicating a neutral trend. The MACD of 0.07 indicates Negative momentum. The RSI at 54.53 is Neutral, neither overbought nor oversold. The STOCH value of 54.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IL:PPBT.

Purple Biotech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BWAY	69 Neutral	755.52M	50.10	7.41%	―	25.65%	―
TEVA	56 Neutral	63.08B	―		―	2.44%	-197.12%
Sector *	54 Neutral	7.49B	5.95	-28.19%	527.79%	26.41%	6.62%
CANF	42 Neutral	47.86M	―		―	―	―
PPBT	32 Underperform	24.99M	―		―	―	71.51%